Quest Diagnostics Inc (NYSE:DGX) SVP Michael E. Prevoznik sold 44,556 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $107.43, for a total transaction of $4,786,651.08. Following the sale, the senior vice president now directly owns 51,321 shares in the company, valued at $5,513,415.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
NYSE DGX traded up $0.69 during trading hours on Wednesday, hitting $106.30. The company’s stock had a trading volume of 716,260 shares, compared to its average volume of 1,059,214. The stock has a fifty day moving average of $103.43 and a 200 day moving average of $102.08. Quest Diagnostics Inc has a twelve month low of $78.95 and a twelve month high of $108.30. The firm has a market capitalization of $14.23 billion, a P/E ratio of 16.85, a PEG ratio of 2.24 and a beta of 0.85. The company has a quick ratio of 0.83, a current ratio of 0.88 and a debt-to-equity ratio of 0.56.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, October 22nd. The medical research company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.71 by $0.05. Quest Diagnostics had a net margin of 9.58% and a return on equity of 15.32%. The firm had revenue of $1.96 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same period last year, the firm earned $1.68 earnings per share. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. On average, analysts predict that Quest Diagnostics Inc will post 6.49 earnings per share for the current year.
Several research firms recently weighed in on DGX. Canaccord Genuity restated a “buy” rating and issued a $113.00 price objective on shares of Quest Diagnostics in a research report on Wednesday, October 23rd. UBS Group decreased their price objective on Quest Diagnostics from $103.00 to $102.00 and set a “neutral” rating on the stock in a research report on Monday, October 21st. Morgan Stanley increased their price objective on Quest Diagnostics from $111.00 to $121.00 and gave the company an “overweight” rating in a research report on Friday, August 23rd. Evercore ISI reissued a “buy” rating and issued a $108.00 target price on shares of Quest Diagnostics in a research note on Thursday, August 8th. Finally, Zacks Investment Research upgraded Quest Diagnostics from a “sell” rating to a “hold” rating and set a $111.00 target price for the company in a research report on Monday, September 30th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $106.85.
Large investors have recently bought and sold shares of the company. Signaturefd LLC raised its position in shares of Quest Diagnostics by 15.9% in the 3rd quarter. Signaturefd LLC now owns 714 shares of the medical research company’s stock valued at $76,000 after acquiring an additional 98 shares during the period. Acropolis Investment Management LLC increased its stake in Quest Diagnostics by 2.2% in the third quarter. Acropolis Investment Management LLC now owns 4,700 shares of the medical research company’s stock valued at $503,000 after purchasing an additional 100 shares in the last quarter. Berman Capital Advisors LLC increased its stake in Quest Diagnostics by 47.7% in the second quarter. Berman Capital Advisors LLC now owns 319 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 103 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its stake in Quest Diagnostics by 2.9% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 3,661 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 103 shares in the last quarter. Finally, IFG Advisory LLC raised its holdings in Quest Diagnostics by 2.5% in the second quarter. IFG Advisory LLC now owns 4,233 shares of the medical research company’s stock worth $430,000 after purchasing an additional 105 shares during the period. Institutional investors and hedge funds own 88.15% of the company’s stock.
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Featured Story: What is the Bid-Ask Spread?
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.